Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – CGTN
The potential vaccine appeared to be safe and can trigger an immune response.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
Business24 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News23 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General18 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General23 hours agoOlder Aussies back increased superannuation tax